抗狂犬病病毒单克隆抗体研究进展  

Advances in monoclonal antibodies against rabies virus

作　　者：刘茜 高洁 曹晨华[2] 朱武洋[1] Liu Qian;Gao Jie;Cao Chenhua;Zhu Wuyang(Key Laboratory of Biosafety,National Health Commission,National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China;Bioactivity Laboratory,Quality Control Department,North China Pharmaceutical Group New Drug Research and Development Co.,Ltd.,Shijiazhuang 052260,China)

机构地区：[1]中国疾病预防控制中心病毒病预防控制所,卫健委生物安全重点实验室,北京102206 [2]华北制药集团新药研究开发有限责任公司质量检验部生物活性实验室,石家庄052260

出　　处：《中华微生物学和免疫学杂志》2024年第4期363-367,共5页Chinese Journal of Microbiology and Immunology

摘　　要：狂犬病作为一种可防不可治的烈性传染病,采取有效的暴露后处置措施至关重要。当人处于狂犬病Ⅲ级暴露下,接种狂犬病免疫球蛋白(rabies immunoglobulin,RIG)是暴露后处置中的重要环节。源于人或动物血浆的RIG存在产能不足、价格偏高等问题,选择有效的抗狂犬病病毒单克隆抗体代替RIG成为一种趋势。作为WHO推荐的、替代RIG的被动免疫制剂,抗狂犬病病毒单克隆抗体具有适应性强、安全性高等优点。鉴于此,本研究拟对已上市的和正在研发的抗狂犬病病毒单克隆抗体进行综述,为该领域的后续研发提供参考和借鉴。Rabies is a vaccine-preventable fulminating infectious disease without effective treatment.Therefore,effective rabies post-exposure prophylaxis becomes more important.Vaccination of rabies immunoglobulin(RIG)is an essential post-exposure treatment after gradeⅢexposure to rabies.At present,insufficient production and high price of RIG derived from human or animal plasma make choosing effective anti-rabies monoclonal antibodies to replace RIG become a trend.As a passive immune agent recommended by WHO to replace RIG,rabies monoclonal antibodies have the advantages of strong adaptability and high safety.In view of this,this paper will review marketed and being developed monoclonal antibodies against rabies virus and provide reference for further research on monoclonal antibodies against rabies virus.

关 键 词：狂犬病 抗狂犬病病毒单克隆抗体 狂犬病免疫球蛋白 

分 类 号：R392-33[医药卫生—免疫学]